Medopad Offers Support for Global COVID-19 Pandemic

▤ Summary

Medopad has worked with clinicians from Imperial College, Guys and St Thomas’s NHS Foundation Trust and Johns Hopkins to create a readily available, out-of-box version of its modular RPM platform configured for tracking COVID-19 that can be deployed in days. To further support healthcare systems, Medopad is also working with its global partners, including Johns Hopkins and Tencent, to clinically validate digital biomarkers to identify individual patient risk for COVID-19 and monitor respiratory symptoms and disease progression using only a smartphone. Medopad’s RPM solution is CE registered and under FDA enforcement discretion and is ready to be deployed in the EU, US, China, Singapore, Hong Kong, Saudi Arabia and beyond for supporting patient care with chronic conditions and configurable for rare diseases. During the COVID-19 crisis, Medopad’s solution can allow hospitals to continuously monitor and engage with their patients without the need to bring them into the healthcare system where there is an elevated risk of them contracting COVID-19,” commented Felix Vaal, Senior Project Manager for Digital Innovation, Chelsea and Westminster Trust. The aim is to adjust the data points collected and focus specifically on cardio-respiratory diseases, diabetes and other conditions which compromise the immune system to identify those who are most at risk should they contract COVID-19,” added Alain Labrique, Associate Professor at Johns Hopkins Bloomberg School of Public Health.

▦ Linked Companies

Medopad

$10M to $25M